The twinrix market research report is one of a series of new reports that provides twinrix market statistics, including the twinrix industry global market size, regional shares, competitors with the twinrix market share, detailed twinrix market segments, market trends, and opportunities, and any further data you may need to thrive in the twinrix industry. This twinrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing vaccination coverage, growing focus on adult immunization, increasing prevalence of liver diseases, rise in healthcare infrastructure by government, and rising approval and adoption of combination vaccines. Major trends in the forecast period include advancements in vaccine technology, advancements in vaccine delivery systems, technological advancements, research and development initiatives, and vaccine development.
The rising prevalence of hepatitis A and B infections is expected to drive the growth of the twinrix market. Hepatitis A and B are viral infections that primarily affect the liver. Hepatitis A is typically transmitted through contaminated food and water and causes acute illness, while hepatitis B is spread through blood and bodily fluids, potentially leading to chronic liver disease. The increase in these infections can be attributed to factors such as poor sanitation and hygiene, unvaccinated populations, unsafe injection practices, increased international travel, and inadequate blood screening. Twinrix is effective in protecting against both hepatitis A and B by providing dual protection, helping reduce the risk of infection and preventing liver-related complications through a convenient vaccination regimen. For example, according to the Centers for Disease Control and Prevention (CDC) in October 2024, hepatitis A cases in the U.S. increased in 2022, with the rate rising to 4.6 cases per 100,000 people, up from 3.6 cases in 2021. As a result, the growing prevalence of hepatitis A and B infections is expected to boost the demand for twinrix.
The growth of the twinrix market is also being fueled by increased vaccination awareness. Vaccination involves administering a vaccine to stimulate the immune system to protect against specific diseases. Awareness around vaccination has been rising due to public health campaigns, educational programs, trusted healthcare recommendations, media outreach, and widespread scientific evidence supporting the safety and effectiveness of vaccines. This heightened awareness is driving demand for Twinrix by informing the public about the risks associated with hepatitis A and B, encouraging preventive measures, and promoting vaccination through travel, healthcare, and public health initiatives. For instance, the UK Health Security Agency reported in June 2023 that during the 2022-2023 school year, a total of 3,502,566 children were vaccinated in the school-aged vaccination program, slightly fewer than the 3,615,536 children vaccinated in the previous year. This increase in vaccination awareness is expected to contribute to growth in the twinrix market.
The growth of the twinrix market is also being driven by the rise in travel and tourism. Travel and tourism encompass the industries and activities related to people traveling for leisure, business, or other reasons, as well as the services provided to support these activities. The increase in travel and tourism is being driven by greater global connectivity, higher disposable incomes, and improved travel services, leading to more tourism activities and an expansion of global destinations. Twinrix is particularly useful for travelers as it provides protection against both hepatitis A and B, ensuring that people are safeguarded from these infections during their travels and can enjoy a safer and more worry-free experience in a variety of destinations. For example, the Office for National Statistics reported in May 2024 that in 2023, UK residents took 6.3 million international business trips, an increase from 4.9 million in 2022. As travel and tourism continue to grow, so too will the demand for twinrix.
The key company operating in the twinrix market is GlaxoSmithKline plc.
North America was the largest region in the twinrix market in 2024. The regions covered in twinrix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the twinrix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Twinrix is a combination vaccine designed to protect against both hepatitis A and hepatitis B viruses. It is typically administered to individuals at increased risk of these infections, such as travelers to regions where these diseases are prevalent or those in specific occupational settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for twinrix include hepatitis A, hepatitis B, and combined immunization. Hepatitis A is a viral liver infection caused by the hepatitis A virus, often transmitted through contaminated food or water or close contact with an infected individual. Twinrix is available in intramuscular injection and pre-filled syringe formulations, offered in both monovalent and combination vaccine compositions. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, serving a broad range of end users such as adults, pediatrics, and geriatrics.
The twinrix market consists of sales of standard-dose, accelerated-dose, vials and combination syringe. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing vaccination coverage, growing focus on adult immunization, increasing prevalence of liver diseases, rise in healthcare infrastructure by government, and rising approval and adoption of combination vaccines. Major trends in the forecast period include advancements in vaccine technology, advancements in vaccine delivery systems, technological advancements, research and development initiatives, and vaccine development.
The rising prevalence of hepatitis A and B infections is expected to drive the growth of the twinrix market. Hepatitis A and B are viral infections that primarily affect the liver. Hepatitis A is typically transmitted through contaminated food and water and causes acute illness, while hepatitis B is spread through blood and bodily fluids, potentially leading to chronic liver disease. The increase in these infections can be attributed to factors such as poor sanitation and hygiene, unvaccinated populations, unsafe injection practices, increased international travel, and inadequate blood screening. Twinrix is effective in protecting against both hepatitis A and B by providing dual protection, helping reduce the risk of infection and preventing liver-related complications through a convenient vaccination regimen. For example, according to the Centers for Disease Control and Prevention (CDC) in October 2024, hepatitis A cases in the U.S. increased in 2022, with the rate rising to 4.6 cases per 100,000 people, up from 3.6 cases in 2021. As a result, the growing prevalence of hepatitis A and B infections is expected to boost the demand for twinrix.
The growth of the twinrix market is also being fueled by increased vaccination awareness. Vaccination involves administering a vaccine to stimulate the immune system to protect against specific diseases. Awareness around vaccination has been rising due to public health campaigns, educational programs, trusted healthcare recommendations, media outreach, and widespread scientific evidence supporting the safety and effectiveness of vaccines. This heightened awareness is driving demand for Twinrix by informing the public about the risks associated with hepatitis A and B, encouraging preventive measures, and promoting vaccination through travel, healthcare, and public health initiatives. For instance, the UK Health Security Agency reported in June 2023 that during the 2022-2023 school year, a total of 3,502,566 children were vaccinated in the school-aged vaccination program, slightly fewer than the 3,615,536 children vaccinated in the previous year. This increase in vaccination awareness is expected to contribute to growth in the twinrix market.
The growth of the twinrix market is also being driven by the rise in travel and tourism. Travel and tourism encompass the industries and activities related to people traveling for leisure, business, or other reasons, as well as the services provided to support these activities. The increase in travel and tourism is being driven by greater global connectivity, higher disposable incomes, and improved travel services, leading to more tourism activities and an expansion of global destinations. Twinrix is particularly useful for travelers as it provides protection against both hepatitis A and B, ensuring that people are safeguarded from these infections during their travels and can enjoy a safer and more worry-free experience in a variety of destinations. For example, the Office for National Statistics reported in May 2024 that in 2023, UK residents took 6.3 million international business trips, an increase from 4.9 million in 2022. As travel and tourism continue to grow, so too will the demand for twinrix.
The key company operating in the twinrix market is GlaxoSmithKline plc.
North America was the largest region in the twinrix market in 2024. The regions covered in twinrix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the twinrix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Twinrix is a combination vaccine designed to protect against both hepatitis A and hepatitis B viruses. It is typically administered to individuals at increased risk of these infections, such as travelers to regions where these diseases are prevalent or those in specific occupational settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for twinrix include hepatitis A, hepatitis B, and combined immunization. Hepatitis A is a viral liver infection caused by the hepatitis A virus, often transmitted through contaminated food or water or close contact with an infected individual. Twinrix is available in intramuscular injection and pre-filled syringe formulations, offered in both monovalent and combination vaccine compositions. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, serving a broad range of end users such as adults, pediatrics, and geriatrics.
The twinrix market consists of sales of standard-dose, accelerated-dose, vials and combination syringe. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Twinrix Market Characteristics4. Twinrix Market Trends And Strategies5. Twinrix Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Twinrix Pricing Analysis & Forecasts30. Global Twinrix Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Twinrix Market32. Recent Developments In The Twinrix Market
3. Twinrix Market Biologic Drug Characteristics
6. Global Twinrix Growth Analysis And Strategic Analysis Framework
8. Twinrix Market Segmentation
9. Global Twinrix Epidemiology Of Clinical Indications
10. Twinrix Market Regional And Country Analysis
11. Asia-Pacific Twinrix Market
12. China Twinrix Market
13. India Twinrix Market
14. Japan Twinrix Market
15. Australia Twinrix Market
16. South Korea Twinrix Market
17. Western Europe Twinrix Market
18. UK Twinrix Market
19. Germany Twinrix Market
20. France Twinrix Market
21. Eastern Europe Twinrix Market
22. North America Twinrix Market
23. USA Twinrix Market
24. Canada Twinrix Market
25. South America Twinrix Market
26. Middle East Twinrix Market
27. Africa Twinrix Market
28. Twinrix Market Competitive Landscape And Company Profiles
29. Global Twinrix Market Pipeline Analysis
33. Twinrix Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Twinrix Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on twinrix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for twinrix ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The twinrix market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Hepatitis A; Hepatitis B; Combined Immunization2) By Formulation: Intramuscular Injection; Pre-Filled Syringes
3) By Composition: Monovalent Vaccines; Combination Vaccines
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Adult; Pediatric; Geriatric
Key Companies Profiled: GlaxoSmithKline plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GlaxoSmithKline plc
